Atlas One · Host Biology · Scale 07 — System

Cholangiocarcinoma

Cholangiocarcinoma includes intrahepatic (iCCA), perihilar, and distal subtypes; FGFR2 fusions and IDH1 mutations (~15% each) define iCCA. Gemcitabine/cisplatin+durvalumab (TOPAZ-1) is first-line; pemigatinib is approved for FGFR2-fusion iCCA; ivosidenib for IDH1-mutant CCA.

Also known as: cholangiocarcinoma, CCA, intrahepatic cholangiocarcinoma, iCCA, perihilar cholangiocarcinoma, Klatskin tumor, biliary tract cancer, BTC, bile duct cancer, FGFR2 fusion CCA

Scale 07 — SystemScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
cholangiocarcinoma

Cholangiocarcinoma

Cholangiocarcinoma includes intrahepatic (iCCA), perihilar, and distal subtypes; FGFR2 fusions and IDH1 mutations (~15% each) define iCCA. Gemcitabine/cisplatin+durvalumab (TOPAZ-1) is first-line; pemigatinib is approved for FGFR2-fusion iCCA; ivosidenib for IDH1-mutant CCA.

Entry Metadata

FieldValue
IDcholangiocarcinoma
NameCholangiocarcinoma
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toFgfr connects-toIdh1 connects-toPd 1 connects-toKras connects-toLiver connects-toBraf connects-toHer2 connects-toGastric Cancer connects-toHcc connects-toPancreatic Cancer connects-toInflammatory Bowel Disease connects-toColorectal Cancer connects-toFibroblast

Sources